Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 20/20 | 1.00 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.75 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.75 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1589816 | 0.88 | AKR1B1 (1.00) | AKR1B1AKR1B10AKR1A1GLO1 | |
| SCHEMBL1590415 | 0.88 | AKR1B1 (1.00) | AKR1B1AKR1B10AKR1A1GLO1 | |
| SCHEMBL9676931 | 0.87 | AKR1B1 (0.77) | AKR1B1AKR1B10AKR1A1GLO1 | |
| Zopolrestat SCHEMBL49012 | 0.85 | AKR1B1 (1.00) | AKR1B1AKR1B10AKR1A1GLO1 | |
| Zopolrestat SCHEMBL29353641 | 0.85 | AKR1B1 (1.00) | AKR1B1AKR1B10AKR1A1GLO1 | |
| Zopolrestat SCHEMBL8505122 | 0.85 | AKR1B1 (1.00) | AKR1B1AKR1B10AKR1A1GLO1 | |
| Zopolrestat SCHEMBL8129027 | 0.85 | AKR1B1 (0.98) | AKR1B1AKR1B10AKR1A1GLO1 | |
| SCHEMBL9740879 | 0.84 | AKR1B1 (0.77) | AKR1B1AKR1B10AKR1A1GLO1 | |
| SCHEMBL10586788 | 0.83 | AKR1B1 (1.00) | AKR1B1 | |
| SCHEMBL9323667 | 0.82 | AKR1B1 (0.80) | AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0880964-B1 | Aldose reductase inhibition in preventing or reversing diabetic cardiomyopathy | PFIZER (US) | 2004-09-29 | — | — | EP | claimed |
| US-5990111-A | ADMINISTERING AN ALDOSE REDUCTASE INHIBITOR TO A HUMAN SUBJECT TO TREAT DIABETIC CARDIOMYOPATHY | PFIZER INC. (US) | 1999-11-23 | — | — | US | claimed |
| EP-0880964-A2 | Aldose reductase inhibition in preventing or reversing diabetic cardiomyopathy | PFIZER INC. (US) | 1998-12-02 | — | — | EP | claimed |
| EP-0880964-B1 | Aldose reductase inhibition in preventing or reversing diabetic cardiomyopathy | PFIZER (US) | 2004-09-29 | — | — | EP | disclosed |
| US-5990111-A | ADMINISTERING AN ALDOSE REDUCTASE INHIBITOR TO A HUMAN SUBJECT TO TREAT DIABETIC CARDIOMYOPATHY | PFIZER INC. (US) | 1999-11-23 | — | — | US | disclosed |
| EP-0880964-A2 | Aldose reductase inhibition in preventing or reversing diabetic cardiomyopathy | PFIZER INC. (US) | 1998-12-02 | — | — | EP | disclosed |
| EP-0222576-B1 | HETEROCYCLIC OXOPHTHALAZINYL ACETIC ACIDS | PFIZER INC. (US) | 1992-03-18 | — | — | EP | disclosed |
| US-4939140-A | ALDOSE REDUCTASE INHIBITORS | PFIZER INC. (US) | 1990-07-03 | — | — | US | disclosed |
| EP-0222576-A2 | Heterocyclic oxophthalazinyl acetic acids | PFIZER INC. (US) | 1987-05-20 | — | — | EP | disclosed |